Nektar Therapeutics (NASDAQ:NKTR)‘s stock had its “buy” rating restated by equities researchers at Aegis in a report issued on Thursday.

A number of other research firms have also recently weighed in on NKTR. Jefferies Group reaffirmed a “buy” rating on shares of Nektar Therapeutics in a report on Thursday, September 8th. Zacks Investment Research raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, September 21st. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $21.00 price objective (up previously from $17.00) on shares of Nektar Therapeutics in a report on Friday, August 5th. Finally, Brean Capital reiterated a “buy” rating and issued a $18.00 target price on shares of Nektar Therapeutics in a research report on Friday, August 5th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $20.50.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded up 0.39% during mid-day trading on Thursday, hitting $12.80. 496,921 shares of the stock traded hands. Nektar Therapeutics has a 12 month low of $10.52 and a 12 month high of $19.98. The company’s market cap is $1.96 billion. The firm has a 50 day moving average of $13.72 and a 200 day moving average of $15.71.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04. Nektar Therapeutics had a negative net margin of 98.87% and a negative return on equity of 8,769.15%. The company earned $36.30 million during the quarter, compared to analysts’ expectations of $32.42 million. During the same quarter in the previous year, the company earned ($0.06) earnings per share. The firm’s revenue for the quarter was down 39.4% on a year-over-year basis. Equities analysts anticipate that Nektar Therapeutics will post ($1.07) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Nektar Therapeutics (NKTR) Rating Reiterated by Aegis” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and republished in violation of United States & international copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/29/nektar-therapeutics-nktr-rating-reiterated-by-aegis.html.

In related news, Director Christopher A. Kuebler sold 7,500 shares of the business’s stock in a transaction dated Friday, September 16th. The shares were sold at an average price of $19.13, for a total transaction of $143,475.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Howard W. Robin sold 93,458 shares of the business’s stock in a transaction dated Thursday, November 17th. The stock was sold at an average price of $13.88, for a total transaction of $1,297,197.04. Following the transaction, the chief executive officer now owns 122,908 shares in the company, valued at $1,705,963.04. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

A number of institutional investors have recently bought and sold shares of NKTR. Price T Rowe Associates Inc. MD raised its position in Nektar Therapeutics by 97.8% in the third quarter. Price T Rowe Associates Inc. MD now owns 1,156,400 shares of the biopharmaceutical company’s stock worth $19,867,000 after buying an additional 571,900 shares during the last quarter. Credit Suisse AG raised its position in Nektar Therapeutics by 3.0% in the third quarter. Credit Suisse AG now owns 499,783 shares of the biopharmaceutical company’s stock worth $8,586,000 after buying an additional 14,639 shares during the last quarter. RA Capital Management LLC raised its position in Nektar Therapeutics by 13.6% in the third quarter. RA Capital Management LLC now owns 3,664,154 shares of the biopharmaceutical company’s stock worth $62,950,000 after buying an additional 439,300 shares during the last quarter. Virtus ETF Advisers LLC raised its position in Nektar Therapeutics by 14.4% in the third quarter. Virtus ETF Advisers LLC now owns 41,365 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 5,212 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in Nektar Therapeutics during the third quarter worth $2,712,000. Hedge funds and other institutional investors own 85.87% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

5 Day Chart for NASDAQ:NKTR

Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.